Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Oct;45(7):866-871.
doi: 10.1111/ced.14270. Epub 2020 Jul 23.

Comparison of gabapentin and hydroxyzine in the treatment of pruritus in patients on dialysis

S Mohammadi Kebar  1 , A Sharghi  2 , M Ghorghani  3 , S Hoseininia  1
Affiliations
Randomized Controlled Trial

Comparison of gabapentin and hydroxyzine in the treatment of pruritus in patients on dialysis

S Mohammadi Kebar et al. Clin Exp Dermatol. 2020 Oct.

Abstract

Background: Pruritus is one of the most common problems in patients with chronic renal failure. Of all patients with end-stage renal disease (ESRD), 60-80% report pruritus during their life.

Aim: To compare the effect of gabapentin (GBP) and hydroxyzine (HYDZ) in treating pruritus in patients on dialysis.

Methods: In a double-blind, randomized, crossover clinical trial, 32 patients on dialysis who reported pruritus were assigned randomly to receive either GBP or HYDZ for 6 weeks; the first group received GBP 100 mg/day orally and the second group received HYDZ 25 mg/day orally for 6 weeks. After this 6-week period (Period 1) there was a washout period of 2 weeks then patients were crossed over to the other drug (the first group receiving HYDZ and second group receiving GBP) and followed up for a further 6 weeks (Period 2). A visual analogue scale was used to measure pruritus intensity in the groups before and after the first and second period.

Results: In Period 1, pruritus severity decreased from 7.1 ± 1.46 at baseline to 2.17 ± 1.82 at 6 weeks in the GBP group (P = 0.001) and from 6.83 ± 2.11 to 2.86 ± 1.67 in the HYDZ group (P = 0.001). In Period 2, pruritus severity decreased from 5.1 ± 1.61 at baseline to 1.56 ± 0.82 at 6 weeks in the GBP group (P < 0.01) and from 5.23 ± 2.11 to 2.1 ± 1.87 in the HYDZ group (P = 0.001).

Conclusion: Results showed that both HYDZ and GBP significantly improved and controlled pruritus in patients on dialysis, with no significant difference observed between the two drugs.

PubMed Disclaimer

References

    1. Akhyani M, Ganji MR, Samadi N et al. Pruritus in hemodialysis patients. BMC Dermatol 2015; 5: 7-13.
    1. Aperis G, Paliouras C, Zervos A et al. The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. J Ren Care 2016; 36: 180-5.
    1. Aşicioǧlu E, Kahveci A, Koç M, Özener Ç. [Uremic pruritus: still itching] (in Turkish). Turk Nephrol Dial Transpl 2011; 27: 89-94.
    1. Kfoury LW, Jurdi MA. Uremic pruritus. J Nephrol 2012; 35: 155-63.
    1. Kimata N, Fuller DS, Saito A et al. Pruritus in hemodialysis patients: results from the Japanese Dialysis Outcomes and Practice Patterns Study (JDOPPS). Hemodial Int 2014; 18: 657-67.

Publication types

MeSH terms